Table 3. Overall Survival for Patients According to Treatment Era.

	Before 2003 n=169				After 2003 n=118
	%	% 5-year OS	% 10-year OS	p	%	% 5-year OS	p
Age				.08			.02
22 – 50	27	61	48		38	73
≥ 50	73	55	37		62	81
Gender				.28			.58
Male	57	56	37		58	80
Female	43	58	44		42	76
# Hepatic Metastases				<.01			<.01
1	38	71	57		25	86
2 – 4	46	57	35		47	84
5 – 7	11	26	16		18	67
≥ 8	5	13	0		10	50
Clinical Risk Score				<.01			.09
0 – 2	59	64	47		54	84
3 – 5	41	47	30		46	70
Margins (cm)				.08			<.01
> 1 cm	44	66	48		31	91
≤ 1 cm	50	52	37		63	77
0 cm	6	50	10		6	38
Margins (mm)				.02			<.01
> 1 mm	84	60	42		86	80
≤ 1 mm	10	30	30		8	88
0 mm	6	50	10		6	38
Size				.32			.16
< 5 cm	69	58	42		81	80
≥ 5 cm	31	54	35		19	70
Primary Lymph Nodes				.03			<.01
Negative	40	65	52		40	90
Positive	60	52	32		60	71
CEA Post-operative				.05			.07
< 5 ng/ml	68	64	44		80	82
≥ 5 ng/ml	32	43	30		20	63
Synchronous Disease				.37			.38
No	58	60	40		41	80
Yes	42	52	39		59	77
Prior Chemotherapy				.80			.45
No	34	60	42		19	87
Yes	66	55	38		81	76